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INTRODUCTION: Agents that target cancers which are deficient in double strand break (DSB) repair, such as poly (ADP-ribose) polymerase-1 (PARP1) inhibitors, have been demonstrated to have highly selective killing (57 fold) of BRCA1-mutated tumors while maintaining minimal toxicity in normal tissues (1) (2) (3) (4) (5) . However, the majority of prostate cancers carry wild-type(WT) BRCA1 (6, 7) and express elevated BRCA1 levels compared to normal prostate tissue (8) . Thus, to enhance the utility of PARP1 inhibitors in patients with prostate cancer, we proposed to sequester WT-BRCA1 from the nucleus where DSBs are repaired to the cytoplasm where apoptosis is activated to render a DSB repair defect and augment the cytotoxic response to PARP1 inhibition in prostate tumor cells. By inducing a DSB repair deficiency, sensitization of prostate cancers to PARP1 inhibitors can be an innovative therapeutic strategy and enhance therapeutic ratio for the majority of patients with prostate cancer.
BODY: We proposed the following tasks for the duration of the grant period as stated below and report the outcomes as follows:
Determine whether IR-induced BRCA1 nuclear export will sensitize prostate cancer cells to PARP1 inhibition, and to determine whether these effects are dependent on CRM1 (Months 1-12): A) Assess the sensitivity of irradiated prostate cancer cells to PARP1 inhibition (Months 1-6) a. Dose response to varying doses of IR (2 -4Gy) and BRCA1 location by IHC b. Time course of BRCA1 nuclear export following IR (4-48hrs following IR) c. Sensitivity of irradiated prostate cancer cells to PARP1 inhibition (dose and time factors) via soft agar colony formation ability B) Determine whether sensitization of irradiated prostate cancer cells to PARP1 inhibition is dependent on CRM1 (Months 6-12) a. Dose response of leptomycin B to inhibit IR-induced BRCA1 nuclear export b. Sensitivity of irradiated prostate cancer cells to PARP1 inhibition following blockade of IR-induced, CRM1-mediated BRCA1 nuclear export RESULTS: Task 1A. We have performed time course and dose response of LNCaP cells to 2-4 Gy IR and assessed BRCA1 location following such treatment. Interestingly, as shown in Fig.1 , BRCA1 subcellular localization is altered (reduced nuclear with concomitant increased cytosolic) as early as16 hrs following IR and persists up to 72hrs (data not shown). Doses of IR as low as 3Gy can achieve this shift of BRCA1 from the nucleus to the cytoplasm. Given that IR can shift BRCA1 from the nucleus to the cytoplasm away from its repair substrates, we next hypothesized that prostate cancer cells exposed to IR will subsequently have a homology-directed recombination repair defect. To test this hypothesis, we utilized LNCaP cells stably expressing the DRGFP HDR repair substrate. In this assay, HDR activity correlates with GFP expression following the induction of a DSB generated by a restriction endonuclease. As shown in Fig. 2 , IR indeed reduced % of GFP positive cells.
Lastly, given that IR reduces nuclear BRCA1 and subsequently generates a HDR repair defect, we next assessed tumor susceptibility to PARP inhibition following IR. Consistent with our hypothesis, sensitivity of irradiated prostate cancer cells to the PARP inhibitor ABT-888 as assessed by colony formation assays is augmented (Fig. 3) .
These results suggest that IR generates a HDR repair defect by sequestering BRCA1 in the cytoplasm and subsequently, prostate tumor cells are rendered susceptible to PARP inhibition.
Additionally, it was previously reported that IR-induced BRCA1 nuclear export in breast cancer cells is dependent on p53. To assess whether BRCA1 nuclear export following IR in prostate cancer cells is also p53 dependent, we next performed the above experiments in PC-3 prostate cancer cells, which are deficient in p53. As shown in Fig. 4 , IR does not result in BRCA1 nuclear export in PC-3 cells. Given this finding, we hypothesized that IR would not augment PC-3 cellular susceptibility to PARP inhibition. This is indeed what is observed (Fig. 5) .
Task 1B. Previous reports suggest that IR-induced BRCA1 export is also dependent on CRM1. To test this hypothesis, we proposed that the CRM1 inhibitor leptomycin B would inhibit IR-induced BRCA1 export. As shown in Fig. 6 , in the presence of leptomycin B, BRCA1 export is no longer apparent following IR. Additionally, leptomycin B prevented the IR-induced deficiency in HR ( Figure  7) , and subsequently prevent IR-induced synthetic lethality with PARP inhibition in LNCaP prostate cancer cells (Figure 8 ). Taken together, our data suggest that indeed IR induces BRCA1 nuclear export to generate a HR deficiency, which subsequently sensitizes prostate tumor cells to PARP inhibition. These effects are all dependent on CRM1, as leptomycin B, which inhibits CRM1, abrogates the observed effects. 
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Figure1. IR increases cytosolic BRCA1 and reduces nuclear BRCA1 in LNCaP human prostate cancer cells. 
Task 2.
To transiently reduce nuclear BRCA1 using a tetracycline (tet)-regulated expression of tr-BRCA1 and determine its effects on HDR and sensitivity to PARP1 inhibition in prostate cancer cells (Months 12-24 
RESULTS:
We have continued to be unsuccessful in generating stable cell lines expressing both the DRGFP repair substrate as well as the inducible tr-BRCA1. However, as we reported in the progress report 2012, we were able to perform most of our proposed experiments using a transiently transfected inducible tr-BRCA1 when needed. As shown in figure 9 , tr-BRCA1 indeed induces BRCA1 nuclear export in both LNCaP (p53 wt) and PC-3 (p53 null) cells. In LNCaP cells, tr-BRCA1 effects are compared with IR (left panel). For PC-3 cells, a time course was performed (right).
Additionally, HR capacity was indeed reduced by tr-BRCA1 ( Figure 10 ). Lastly, consistent with our hypothesis, tr-BRCA1 reduced colony forming ability of LNCaP and PC-3 cells when combined with the PARP inhibitor ABT-888 ( Figure 11 ).
Furthermore, we attempted to assess the mechanism of cytotoxicity observed in prostate cancer cells treated with radiation followed by PARP1 inhibition. Because of our previous findings in other cancer types such as head and neck and triple negative breast cancer (Nowsheen, S, et al. PLOS One 2011; Nowsheen et al. PLOS One 2012), we first hypothesized that the mechanism is due to activation of apoptosis. Interestingly, we could not detect cleavage of caspase-3 as our marker for apoptosis. We also attempted Annexin V analysis by flow cytometry and did not observe any differences amongst our treatment groups (data not shown). Other reports suggest cytotoxicity of PARPi, in particular in prostate cancer, is due to changes in cell cycle distribution, especially accumulation in the G2/M phase. Thus, we assessed cell cycle distribution using flow cytometry following our various treatments.
As shown in Figure 12 , indeed in the LNCaP prostate cancer cells, which are sensitive to the therapeutic strategy of radiation followed by PARPi, there is an increase in the proportion of cells in the G2/M cell cycle phase. In contrast, the cell cycle distribution of PC-3 cells, which are insensitive to these treatments, is not changed. Furthermore, we assessed whether persistent DNA damage as measured by persistent g-H2AX foci is observed in cells sensitive to the combination. Indeed this is the case (Figure 13 ). We are currently continuing to investigate whether these mechanisms are also observed using Tr-BRCA1. 
To validate the role of induced DSB repair deficiency and sensitivity to PARP1 inhibition in vivo with prostate tumor xenograft models (Months 24-36).
A) Determine optimal cell number for grafting of LNCaP xenografts in mice (Months 24-36) B) To assess sensitivity of irradiated prostate tumor xenografts to PARP1 inhibition by tumor growth delay assays (Months 24-36) C) To assess resistance of prostate tumor xenografts to PARP1 inhibition following tetrepression of tr-BRCA1 expression by tumor growth delay assays (Months 24-36).
RESULTS:
Unfortunately, we were unsuccessful in generating prostate cancer xenografts despite varying the tumor cell number. Our initial experiment was started 12/14/2011. We injected 35 athymic nude mice with 10 million LNCaP cells in each flank. These did not take.
Our second trial was 3 months later 3/21/2012, with inoculation of 2.5 million LnCap cells into both flanks of again 35 male athymic nude mice.We used a 2:1 ratio matrigel:cells in media (per Dr. Buchsbaum's (mentoring committee member with extensive animal model experience) suggestion; these also were not successful in growing LnCap). Treatment groups were going to be:
Due to the low take rate of the Lncap cell line (<20%) and the slow progression of tumor growth once it was established (4-6 months), we have not been able to accumulate adequate results at this time. Tumors were collected 6 months post-inoculation on 9/27/12 as follows:
One tumor from flank of one mouse was minced into 1-2 mm fragments -5 vials with 10% DMSO, 10% FBS, 50 U/ml heparin in DMEM -5 vials with 10% DMSO in DMEM -stored in -80 C for re-implantation 4 small tumors (3 different mice, one mouse had both L and R flank tumors), and 1 large tumor were collected and fresh frozen, stored at -80 C for protein extraction to be used in Western blotting.
We are currently awaiting IACUC approval for our protocol modification to allow for implanting the "successful" xenografts as explants corrected for tumor weight to perform the proposed experiments.
REPORTABLE OUTCOMES:
We have presented data generated from this training grant at the ASTRO Annual Meeting 2010 and 2011. Both were invited oral presentations. Additionally, the 2010 presentation won the basic science award at ASTRO. We are currently preparing a manuscript to report the results of our study supported by this DOD grant.
Importantly, training that occurred as a result of this grant has stimulated other research projects that investigate other methods of targeting DNA repair to render tumor cells susceptible to PARP inhibition. These projects have resulted in multiple grant awards, including a translational scholar award from the Sidney Kimmel Foundation for Cancer Research, and a career development award from the AACR/Genentech BioOncology. Most recently, we received a career catalyst award from the Susan G. Komen Foundation for Cancer Research. We have also submitted grant applications to the American Cancer Society as well as Department of Defense BCRP and have become a UAB Breast SPORE Project (Project 2) that is currently under review.
Also, publications have resulted as a result of these "spin-off" projects. They are listed as follows: 
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